Ukr.Biochem.J. 2020; Volume 92, Issue 6, Nov-Dec, pp. 105-112

doi: https://doi.org/10.15407/ubj92.06.105

The content of pro-inflammatory cytokines IL-1β, IL-6, IL-17A and TNFα in the blood of patients with type 2 diabetes after therapy with metformin

K. P. Zak*, O. V. Furmanova, V. V. Popova, Ya. A. Sayenko

SI “V.P. Komisarenko Institute of Endocrinology and Metabolism of National Academia of Medical Sciences of Ukraine”, Kyiv;
*e-mail: kpzak2017@gmail.com

Received: 28 February 2020; Accepted: 13 November 2020

Currently the world society is extremely worried about the global increase in the number of patients with diabetes on our planet. Annually 4 million people die of this disease, and the cost of its treatment reaches trillions of dollars. A new highly effective oral antidiabetic drug  metformin (1,1-dimethylbiguanide hydrochloride) is one of the most common hypoglycemic remedies  currently prescribed for the first-line treatment of patients with type 2 diabetes (T2D). However, the mechanism of its curative effect is still not clear. The results of our study showed  that metformin treatment of patients with newly diagnosed T2D was followed by  pronounced normalization of  the increased levels of pro-inflammatory cytokines (IL-1β, IL-6, IL-17A and TNFα),  inflammation indexes and lymphocyte’s immunophenotype. The obtained data confirm the existing hypothesis about the inflammatory nature of T2D and indicate that the immune system, in particular proinflammatory cytokines, plays a significant role in the mechanism of the curative effect of metformin at  T2D.

Keywords: , , ,


References:

  1. IDF Diabetes Atlas, 8th edition. 2017.
  2. American Diabetes Association. Standards of Medical Care in Diabetes-2019 Abridged for Primary Care Providers. Clin Diabetes. 2019;37(1):11-34. PubMed, PubMedCentral, CrossRef
  3. Inzucchi SE. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. Diabetes Care. 2017;40(8):1128-1132.  PubMed, CrossRef
  4. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576.  PubMed, CrossRef
  5. Song R. Mechanism of Metformin: A Tale of Two Sites. Diabetes Care. 2016;39(2):187-189. PubMed, CrossRef
  6. Marshall SM. 60 years of metformin use: a glance at the past and a look to the future. Diabetologia. 2017;60(9):1561-1565.
    PubMed, CrossRef
  7. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498.  PubMed, CrossRef
  8. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio DA, Davies MJ. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221-228. PubMed, CrossRef
  9. Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017;60(9):1601-1611. PubMed, PubMedCentral, CrossRef
  10. Perreault L, Pan Q, Schroeder EB, Kalyani RR, Bray GA, Dagogo-Jack S, White NH, Goldberg RB, Kahn SE, Knowler WC, Mathioudakis N, Dabelea D.  Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care. 2019;42(9):1809-1815. PubMed, PubMedCentral, CrossRef
  11. American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S29-S33. PubMed, CrossRef
  12. Valencia WM, Palacio A, Tamariz L, Florez H. Metformin and ageing: improving ageing outcomes beyond glycaemic control. Diabetologia. 2017;60(9):1630-1638. PubMed, PubMedCentral, CrossRef
  13. Donath MY. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia. 2016;59(4):679-682. PubMed, CrossRef
  14. Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O’Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA. A guiding map for inflammation. Nat Immunol. 2017;18(8):826-831. PubMed, PubMedCentral, CrossRef
  15. Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, McNeilly AD, Balfour DJK, Savinko T, Wong AKF, Viollet B, Sakamoto K, Fagerholm SC, Foretz M, Lang CC, Rena G. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016;119(5):652-665. PubMed, PubMedCentral, CrossRef
  16. Cameron AR, Morrison V, McNeilly AD, Forteath C,  Beall C, Stewart CA, Balfour DJK, Suther-LAND C,  Sakamoto K, Fagerholm SC, Rena G. The anti-inflammatory role of metformin. Diabetes. 2015;64(Suppl 1): A471.
  17. Furmanova O, Muz N, Popova V, Sayenko Y, Orlenko V, Ivas’kiva R, et al.  Proinflammatory cytokines as biomarkers of effective metformin therapy in patients with type 2 diabetes. Diabetologia. 2019. 62(Suppl 1):S25–S25.
  18. Tron’ko M, Furmanova O, Popova V, Sayenko Ya, Orlenko V, Ivas’kiva K, et al. Anti-inflammatory and immune-mediated effects of metformin therapy in patients with type 2 diabetes. Diabetologia. 2018. 61 (Suppl 1): S2632.
  19. Wannamethee SG, Papacosta O, Lawlor DA, Whincup PH, Lowe GD, Ebrahim S, Sattar N. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study. Diabetologia. 2012;55(1):80-87. PubMed, CrossRef
  20. Shitole SG, Biggs ML, Reiner AP, Mukamal KJ, Djoussé L, Ix JH, Barzilay JI, Tracy RP, Siscovick D, Kizer JR. Soluble CD14 and CD14 Variants, Other Inflammatory Markers, and Glucose Dysregulation in Older Adults: The Cardiovascular Health Study. Diabetes Care. 2019;42(11):2075-2082. PubMed, PubMedCentral, CrossRef
  21. Zak KP, Tron’ko ND, Popov VV, Butenko AK. Diabetes. Immunity. Cytokines. K.: Kniga plyus, 2015. 485 p. (In Russian).
  22. Wang X, Zhang G, Jiang X, Zhu H, Lu Z, Xu L. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. Atherosclerosis. 2014;234(1):206-213. PubMed, CrossRef
  23. Hattori Y, Hattori K, Hayashi T. Pleiotropic benefits of metformin: macrophage targeting its anti-inflammatory mechanisms. Diabetes. 2015;64(6):1907-1909. PubMed, PubMedCentral, CrossRef
  24. Womack J, Tien PC, Feldman J, Shin JH, Fennie K, Anastos K, Cohen MH, Bacon MC, Minkoff H. Obesity and immune cell counts in women. Metabolism. 2007;56(7):998-1004. PubMed, PubMedCentral, CrossRef
  25. Fabbrini E, Cella M, McCartney SA, Fuchs A, Abumrad NA, Pietka TA, Chen Z, Finck BN, Han DH, Magkos F, Conte C, Bradley D, Fraterrigo G, Eagon JC, Patterson BW, Colonna M, Klein S. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology. 2013;145(2):366-374. PubMed, PubMedCentral, CrossRef
  26. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P, Liu LG. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36(1):166-175. PubMed, PubMedCentral, CrossRef
  27. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465-476. PubMed, CrossRef
  28. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517-1526. PubMed, CrossRef
  29. Cieślak M, Cieślak M. Role of purinergic signalling and proinflammatory cytokines in diabetes. Clin Diabetol. 2017;6(3):90–100.  CrossRef
  30. Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 2013;39(6):524-531. PubMed, CrossRef
  31. Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, Berg JK, Landschulz WH. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care. 2013;36(8):2239-2246. PubMed, PubMedCentral, CrossRef
  32. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812-817. PubMed, CrossRef
  33. Chen C, Shao Y, Wu X, Huang C, Lu W. Elevated interleukin-17 levels in patients with newly diagnosed type 2 diabetes mellitus. Biochem Physiol. 2016;(2):206.   CrossRef
  34. Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287-292. PubMed, CrossRef
  35. Kumar S, Wilson B, Watson L, Alsop J. Obesity is associated with poorer clinical outcomes following insulin initiation for patients with type 2 diabetes. In: Minutes of the 44th Genral Assembly of the European Association for the Study of Diabetes. Diabetologia. 2009;52(Suppl 1):S1-S550. CrossRef
  36. Tamariz L, Hare JM. Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. Eur Heart J. 2010;31(7):768-770. PubMed, CrossRef
  37. Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. Diabetes Care. 2016;39(Suppl 2):S244-S252. PubMed,CrossRef
  38. Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62(9):1550-1560.   PubMed, PubMedCentral, CrossRef
  39. Chae JS, Paik JK, Kang R, Kim M, Choi Y, Lee SH, Lee JH. Mild weight loss reduces inflammatory cytokines, leukocyte count, and oxidative stress in overweight and moderately obese participants treated for 3 years with dietary modification. Nutr Res. 2013;33(3):195-203. PubMed, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.